161 related articles for article (PubMed ID: 27895797)
1. UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimens.
Cui C; Shu C; Cao D; Yang Y; Liu J; Shi S; Shao Z; Wang N; Yang T; Liang H; Zou S; Hu S
Oncol Lett; 2016 Nov; 12(5):4231-4237. PubMed ID: 27895797
[TBL] [Abstract][Full Text] [Related]
2. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
Liu D; Li J; Gao J; Li Y; Yang R; Shen L
BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
[TBL] [Abstract][Full Text] [Related]
3. The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients.
Lee CK; Chon HJ; Kwon WS; Ban HJ; Kim SC; Kim H; Jeung HC; Chung J; Rha SY
Genomics Inform; 2022 Sep; 20(3):e29. PubMed ID: 36239106
[TBL] [Abstract][Full Text] [Related]
4. A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes.
Tsunedomi R; Hazama S; Fujita Y; Okayama N; Kanekiyo S; Inoue Y; Yoshino S; Yamasaki T; Suehiro Y; Oba K; Mishima H; Sakamoto J; Hamamoto Y; Oka M
Int J Oncol; 2014 Oct; 45(4):1381-90. PubMed ID: 25175642
[TBL] [Abstract][Full Text] [Related]
5. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
Hazama S; Mishima H; Tsunedomi R; Okuyama Y; Kato T; Takahashi K; Nozawa H; Ando H; Kobayashi M; Takemoto H; Nagata N; Kanekiyo S; Inoue Y; Hamamoto Y; Fujita Y; Hinoda Y; Okayama N; Oba K; Sakamoto J; Oka M
Cancer Sci; 2013 Dec; 104(12):1662-9. PubMed ID: 24033692
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.
Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Jang IJ; Lee DH; Lee JS
J Clin Oncol; 2006 May; 24(15):2237-44. PubMed ID: 16636344
[TBL] [Abstract][Full Text] [Related]
7. Differences in UGT1A1, UGT1A7, and UGT1A9 polymorphisms between Uzbek and Japanese populations.
Maeda H; Hazama S; Shavkat A; Okamoto K; Oba K; Sakamoto J; Takahashi K; Oka M; Nakamura D; Tsunedomi R; Okayama N; Mishima H; Kobayashi M
Mol Diagn Ther; 2014 Jun; 18(3):333-42. PubMed ID: 24453052
[TBL] [Abstract][Full Text] [Related]
8. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Carlini LE; Meropol NJ; Bever J; Andria ML; Hill T; Gold P; Rogatko A; Wang H; Blanchard RL
Clin Cancer Res; 2005 Feb; 11(3):1226-36. PubMed ID: 15709193
[TBL] [Abstract][Full Text] [Related]
9. Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer.
Fujita K; Ando Y; Nagashima F; Yamamoto W; Eodo H; Araki K; Kodama K; Miya T; Narabayashi M; Sasaki Y
Cancer Chemother Pharmacol; 2007 Sep; 60(4):515-22. PubMed ID: 17406868
[TBL] [Abstract][Full Text] [Related]
10. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.
Cecchin E; Innocenti F; D'Andrea M; Corona G; De Mattia E; Biason P; Buonadonna A; Toffoli G
J Clin Oncol; 2009 May; 27(15):2457-65. PubMed ID: 19364970
[TBL] [Abstract][Full Text] [Related]
11. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).
Gagné JF; Montminy V; Belanger P; Journault K; Gaucher G; Guillemette C
Mol Pharmacol; 2002 Sep; 62(3):608-17. PubMed ID: 12181437
[TBL] [Abstract][Full Text] [Related]
12. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs.
Villeneuve L; Girard H; Fortier LC; Gagné JF; Guillemette C
J Pharmacol Exp Ther; 2003 Oct; 307(1):117-28. PubMed ID: 12944498
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer.
Li M; Wang Z; Guo J; Liu J; Li C; Liu L; Shi H; Liu L; Li H; Xie C; Zhang X; Sun W; Fang S; Bi X
Onco Targets Ther; 2014; 7():1653-61. PubMed ID: 25285015
[TBL] [Abstract][Full Text] [Related]
14. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
Martinez-Balibrea E; Abad A; Martínez-Cardús A; Ginés A; Valladares M; Navarro M; Aranda E; Marcuello E; Benavides M; Massutí B; Carrato A; Layos L; Manzano JL; Moreno V
Br J Cancer; 2010 Aug; 103(4):581-9. PubMed ID: 20628391
[TBL] [Abstract][Full Text] [Related]
15. Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
Lévesque E; Bélanger AS; Harvey M; Couture F; Jonker D; Innocenti F; Cecchin E; Toffoli G; Guillemette C
J Pharmacol Exp Ther; 2013 Apr; 345(1):95-101. PubMed ID: 23386248
[TBL] [Abstract][Full Text] [Related]
16. XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer.
Cui C; Shu C; Yang Y; Liu J; Shi S; Shao Z; Wang N; Yang T; Hu S
Oncol Lett; 2014 Oct; 8(4):1864-1872. PubMed ID: 25202427
[TBL] [Abstract][Full Text] [Related]
17. Association analysis of UGT1A genotype and haplotype with SN-38 glucuronidation in human livers.
Wang H; Bian T; Jin T; Chen Y; Lin A; Chen C
Pharmacogenomics; 2014 Apr; 15(6):785-98. PubMed ID: 24897286
[TBL] [Abstract][Full Text] [Related]
18. Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk.
Lankisch TO; Schulz C; Zwingers T; Erichsen TJ; Manns MP; Heinemann V; Strassburg CP
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):695-701. PubMed ID: 18349289
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene.
Lankisch TO; Vogel A; Eilermann S; Fiebeler A; Krone B; Barut A; Manns MP; Strassburg CP
Mol Pharmacol; 2005 May; 67(5):1732-9. PubMed ID: 15716465
[TBL] [Abstract][Full Text] [Related]
20. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
Gao J; Zhou J; Li Y; Lu M; Jia R; Shen L
Med Oncol; 2013; 30(3):604. PubMed ID: 23686699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]